KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Opko Health (OPK) Other Operating Expenses (2016 - 2025)

Opko Health (OPK) has disclosed Other Operating Expenses for 16 consecutive years, with $103.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Operating Expenses fell 13.28% year-over-year to $103.5 million, compared with a TTM value of $377.3 million through Dec 2025, down 17.23%, and an annual FY2025 reading of $377.3 million, down 17.23% over the prior year.
  • Other Operating Expenses was $103.5 million for Q4 2025 at Opko Health, up from $19.7 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $375.1 million in Q1 2021 and bottomed at $19.7 million in Q3 2025.
  • Average Other Operating Expenses over 5 years is $174.0 million, with a median of $158.7 million recorded in 2023.
  • The sharpest move saw Other Operating Expenses surged 143.06% in 2021, then tumbled 51.81% in 2022.
  • Year by year, Other Operating Expenses stood at $305.2 million in 2021, then plummeted by 51.81% to $147.1 million in 2022, then rose by 7.88% to $158.7 million in 2023, then fell by 24.8% to $119.3 million in 2024, then dropped by 13.28% to $103.5 million in 2025.
  • Business Quant data shows Other Operating Expenses for OPK at $103.5 million in Q4 2025, $19.7 million in Q3 2025, and $126.8 million in Q2 2025.